InvestorsHub Logo
Followers 45
Posts 5124
Boards Moderated 0
Alias Born 01/27/2012

Re: Guzzi62 post# 423127

Monday, 07/17/2023 12:39:27 AM

Monday, July 17, 2023 12:39:27 AM

Post# of 458751

It looks like Anavex has employed a robust data analytics method to increase strength of low-N trial results. This will be helpful in future rare disease trials as well.



“When you see what we did you will know why we did things the way we did”

Some need answers and adas cog scores now to justify their belief. I hope they dont get it until the end. I hope Dr. Missling keeps on his plan and gives them nothing. What “they” dont understand is that the market is just as much in the dark and has a hard time calculating Anavex’s moves. This doesntmatter because its all about me isms is t it?

This drug and its “method to market” is not for the prideful and eccentric to understand completely, rather their intellect gets in their way. Kind of reminds me of an old story in the “big book” on the coffee table. They get stuck on traditional and historical methods and Dr. Missling and his team he has compiled have done anything but march to the beat of Pharmas drum. The message is clear, the plan is in place, when the time is right all in it’s magnificent glory will be shared.

Good luck with your thesis, makes me wonder how those that have so many questions after almost a decade of no bad trial results still invest their hard earned money here. This is except those that have made nickels and dimes along the way that are “playing with house money”. What ever makes you sleep better at night, heck, for that matter you should pull those shares and keep them under your mattress safe and sound with all the rest of your treasures on earth.

Two philosophies and two priorities only one eternity.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News